NAVICAN PRECISION CANCER CARE
DEAD

Serial Number

87978077

Owner

IHC Health Services, Inc.

Attorney

Joshua G. Gigger

First Use Date

Apr 23, 2018

Filing Date

May 30, 2017

Add to watchlist:

No watchlists yet
View on USPTO

NAVICAN PRECISION CANCER CARE Trademark

Serial Number: 87978077 • Registration: 5771247

NAVICAN PRECISION CANCER CARE is a trademark filed by IHC Health Services, Inc. on May 30, 2017. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

IHC Health Services, Inc. (82 trademarks)

36 South State Street, Suite 2200
Salt Lake City, UT 84111

Entity Type: 03

Navican Genomics, Inc. (7 trademarks)

4655 Executive Drive, Suite 230
San Diego, CA 92130

Entity Type: 03

Trademark Details

Filing Date

May 30, 2017

Registration Date

June 4, 2019

First Use Anywhere

April 23, 2018

First Use in Commerce

April 23, 2018

Published for Opposition

November 7, 2017

Cancellation Date

December 19, 2025

Goods & Services

Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 19, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 4, 2024 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 14, 2019 ASGN
REGISTERED-PRINCIPAL REGISTER
Jun 4, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 3, 2019 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 2, 2019 CNPR
EXAMINER'S AMENDMENT ENTERED
May 2, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 2, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
May 2, 2019 GNEA
SU-EXAMINER'S AMENDMENT WRITTEN
May 2, 2019 SNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 4, 2018 GNFN
FINAL REFUSAL E-MAILED
Oct 4, 2018 GNFR
SU - FINAL REFUSAL - WRITTEN
Oct 4, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 14, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 13, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 13, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 2, 2018 GNRN
NON-FINAL ACTION E-MAILED
Aug 2, 2018 GNRT
SU - NON-FINAL ACTION - WRITTEN
Aug 2, 2018 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Jul 13, 2018 SUPC
DIVISIONAL PROCESSING COMPLETE
Jul 13, 2018 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 13, 2018 AITU
USE AMENDMENT FILED
Jun 29, 2018 IUAF
DIVISIONAL REQUEST RECEIVED
Jun 29, 2018 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Jun 29, 2018 ERTD
TEAS STATEMENT OF USE RECEIVED
Jun 29, 2018 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 2, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 7, 2017 NPUB
PUBLISHED FOR OPPOSITION
Nov 7, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 18, 2017 NONP
ASSIGNED TO LIE
Oct 1, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 16, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 26, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 26, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 26, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 26, 2017 CNEA
EXAMINER'S AMENDMENT ENTERED
Aug 24, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 24, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 24, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 24, 2017 CNEA
ASSIGNED TO EXAMINER
Aug 17, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 6, 2017 NWOS
NEW APPLICATION ENTERED
Jun 2, 2017 NWAP